BMS-599626

Synonyms: AC480
BMS-599626 (AC480) 是一种选择性的口服生物利用度 HER1 和 HER2 抑制剂,其 IC50 分别为 20 和 30 nM,对 HER4 的 IC50 值为 190 nM,对 VEGFR2、c-Kit、Lck、MEK 的抑制强度降低了100倍,可抑制肿瘤细胞增殖,并有可能增加肿瘤对放疗的反应。
产品编号: MS-L08096 纯度: 98.56% CAS No.: 714971-09-2 分子式: C27H27FN8O3 分子量: 530.55
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

BMS-599626 (AC480) 是一种选择性的口服生物利用度 HER1 和 HER2 抑制剂,其 IC50 分别为 20 和 30 nM,对 HER4 的 IC50 值为 190 nM,对 VEGFR2、c-Kit、Lck、MEK 的抑制强度降低了100倍,可抑制肿瘤细胞增殖,并有可能增加肿瘤对放疗的反应。

生物实验数据

生物活性 BMS-599626 (AC480) is a selective, orally bioavailable inhibitor of HER1 and HER2 with IC50 values of 20 and 30 nM, respectively, and an IC50 of 190 nM for HER4, exhibiting 100-fold reduced potency against VEGFR2, c-Kit, Lck, and MEK, and it inhibits tumor cell proliferation and may potentially enhance the tumor response to radiotherapy.
IC50 & Target HER1:20 nM, HER2:30 nM, HER4:190 nM
体外研究
(In Vitro)

BMS-599626 inhibits the proliferation of tumor cells that are dependent on HER1/HER2 signaling. BMS-599626 (0.03-8 μM; 1 huors) results in the inhibition of receptor autophosphorylation, as well as MAPK phosphorylation, with IC50s of 0.3 and 0.22 μM, respectively, in Sal2 cells which express a CD8HER2 fusion protein.
BMS-599626 abrogates HER1 and HER2 signaling and inhibited the proliferation of tumor cell lines that are dependent on these receptors, with IC50 in the range of 0.24 to 1 μM.In GEO cells, HER1 phosphorylation is stimulated by treatment with EGF and is inhibited by BMS-599626 (IC50=0. 75 μM).There is also nearly complete inhibition of EGF-dependent MAPK (0. 8 μM) but only partial inhibition of AKT signaling.The latter likely reflects the activation of AKT by multiple upstream signals.Treatment of N87 cells with BMS-599626 leads to the inhibition of HER2 (0. 38 μM), which is expressed to a high level because of gene amplification, as well as MAPK and AKT phosphorylation (0.35 μM for both).
At the molecular level, in HN-5 cells the agent inhibited the expression of pEGFR, pHER2, cyclins D and E, pRb, pAkt, pMAPK, pCDK1 and 2, CDK 6, and Ku70 proteins. The drug also induced accumulation of cells in the G1 cell cycle phase, inhibited cell growth, enhanced radiosensitivity, and prolonged the presence of γ-H AX foci up to 24 h after radiation.

体内研究
(In Vivo)

BMS-599626 (60-240 mg/kg; p.o.; daily for 14 days) results in a dose-dependent inhibition of Sal2 tumor growth.
BMS599626 treatment results in the inhibition of GEO xenograft tumor growth when given once daily for 14 days. In addition to efficacy in the Sal2, GEO, and KPL4 models, BMS-599626 has similar antitumor activity in other HER2 amplified xenograft models including the BT474 breast and N87 gastric tumors, as well as other HER1-overexpressing non-small-cell lung tumors (A549 and L2987).
BMS599626 given before and during irradiation improved the radioresponse of HN5 tumors in vivo.

Animal Model: Athymic female nude mice (nu/nu mice, Sal2 tumor model)
Dosage: 60, 120, 240 mg/kg
Administration: Oral; daily for 14 days
Result: Resulted in a dose-dependent inhibition of Sal2 tumor growth.
性状 固体
颜色 White to off-white

化学信息

分子量 530.55
分子式 C27H27FN8O3
CAS No. 714971-09-2
别名 AC480

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 110 mg/mL (207.33 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.8848 mL9.4242 mL18.8484 mL47.1209 mL
5 mM0.3770 mL1.8848 mL3.7697 mL9.4242 mL
10 mM0.1885 mL0.9424 mL1.8848 mL4.7121 mL
15 mM0.1257 mL0.6283 mL1.2566 mL3.1414 mL
20 mM0.0942 mL0.4712 mL0.9424 mL2.3560 mL
25 mM0.0754 mL0.3770 mL0.7539 mL1.8848 mL
30 mM0.0628 mL0.3141 mL0.6283 mL1.5707 mL
40 mM0.0471 mL0.2356 mL0.4712 mL1.1780 mL
50 mM0.0377 mL0.1885 mL0.3770 mL0.9424 mL
60 mM0.0314 mL0.1571 mL0.3141 mL0.7853 mL
80 mM0.0236 mL0.1178 mL0.2356 mL0.5890 mL
100 mM0.0188 mL0.0942 mL0.1885 mL0.4712 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础